Failure to Complete Baseline AIMS Assessments for Residents on Antipsychotics
Penalty
Summary
The facility failed to complete baseline Abnormal Involuntary Movement Scale (AIMS) assessments for two residents who were prescribed antipsychotic medications. For one resident with diagnoses including acute and chronic respiratory failure with hypoxia and major depressive disorder, Latuda was ordered, and the care plan included monitoring for adverse reactions such as tardive dyskinesia. However, no baseline AIMS assessment was documented from the time of the antipsychotic prescription through the review period. Similarly, another resident with diagnoses of insomnia and major depressive disorder was prescribed Aripiprazole, with orders and care plans specifying monitoring for side effects, including extrapyramidal symptoms. Despite these directives, no baseline AIMS assessment was completed for this resident during the relevant timeframe. The DON confirmed that AIMS assessments were not performed upon admission for either resident. Facility policy required AIMS testing for residents receiving antipsychotic medications, but this was not followed in these cases.